#Antibody

Generative Antibody Design Cracks 'Undruggable' Targets

Mabylon Raises €31.8M to Advance Allergy Antibody Pipeline

Mabylon, a Swiss biotech, secured €31.8 million in new funding. This investment will advance its lead peanut allergy program and early-stage pipeline. The funding came from existing private investors, including former Roche management and board members.